Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBIT Margin: 2011-2025

Historic EBIT Margin for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to 15.91%.

  • Ani Pharmaceuticals' EBIT Margin rose 2974.00% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.70%, marking a year-over-year increase of 660.00%. This contributed to the annual value of 0.10% for FY2024, which is 955.00% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' EBIT Margin is 15.91%, which was up 142.04% from 6.57% recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EBIT Margin registered a high of 27.19% during Q1 2021, and its lowest value of -38.94% during Q4 2021.
  • For the 3-year period, Ani Pharmaceuticals' EBIT Margin averaged around 6.98%, with its median value being 9.27% (2023).
  • As far as peak fluctuations go, Ani Pharmaceuticals' EBIT Margin skyrocketed by 4,294bps in 2021, and later crashed by 5,696bps in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' EBIT Margin (Quarterly) stood at -38.94% in 2021, then surged by 4,087bps to 1.93% in 2022, then skyrocketed by 318bps to 5.11% in 2023, then plummeted by 741bps to -2.30% in 2024, then skyrocketed by 2,974bps to 15.91% in 2025.
  • Its EBIT Margin was 15.91% in Q3 2025, compared to 6.57% in Q2 2025 and 13.29% in Q1 2025.